Erratum to: Neuropsychiatric symptoms in patients with dementias associated with cortical Lewy bodies: Pathophysiology, clinical features, and pharmacological management (Drugs Aging (2013) 30, (603-611) DOI: 10.1007/s40266-013-0092-x);Neuropsychiatric symptoms in patients with dementias associated with cortical lewy bodies: Pathophysiology, clinical features, and pharmacological management

Drugs and Aging

Volumn 30, Issue 8, 2013, Pages 603-611

  Ballard, Clive ^a   Aarsland, Dag ^b   Francis, Paul ^a   Corbett, Anne ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DONEPEZIL; LEVODOPA; MELATONIN; MEMANTINE; METHYLPHENIDATE; OLANZAPINE; PLACEBO; PRAMIPEXOLE; PRAZOSIN; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TACRINE;

AGED; ALZHEIMER DISEASE; ANXIETY; APATHY; BRIEF PSYCHIATRIC RATING SCALE; CEREBROVASCULAR DISEASE; CHOLINERGIC TRANSMISSION; CLINICAL GLOBAL IMPRESSION SCALE; COHORT ANALYSIS; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DRUG DOSE TITRATION; DRUG SAFETY; DYSTONIA; ELECTROCONVULSIVE THERAPY; ENZYME ACTIVITY; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; HALLUCINATION; HUMAN; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NEUROBIOLOGY; NEUROPSYCHIATRIC INVENTORY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PARASOMNIA; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; SYNAPSE; TEMPORAL CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; VISUAL HALLUCINATION;

EID: 84880850040     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0195-z     Document Type: Erratum

References (72)

1. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-72.
2. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387-92.
3. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2005;20(10):1255-63.
4. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormack F, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology. 2002;59(11):1714-20.
5. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697-707.
6. Ballard C, Holmes C, McKeith I, Neill D, O'Brien J, Cairns N, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry. 1999;156(7):1039-45.
7. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology. 1996;47(5):1148-52.
8. Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007;78(1):36-42.
9. Ballard C, McKeith I, Harrison R, O'Brien J, Thompson P, Lowery K, et al. A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr/IPA. 1997;9(4):381-8.
10. Ballard C, O'Brien J, Coope B, Fairbairn A, Abid F, Wilcock G. A prospective study of psychotic symptoms in dementia sufferers: psychosis in dementia. Int Psychogeriatr/IPA. 1997;9(1):57-64.
11. Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17(3):146-57.
12. Rongve A, Boeve BF, Aarsland D. Frequency and correlates of caregiver-reported sleep disturbances in a sample of persons with early dementia. J Am Geriatr Soc. 2010;58(3):480-6.
13. Fritze F, Ehrt U, Hortobagyi T, Ballard C, Aarsland D. Depressive symptoms in Alzheimer's disease and Lewy body dementia: a one-year follow-up study. Dementia Geriatr Cogn Disord. 2011;32(2):143-9.
14. Hynninen MJ, Breitve MH, Rongve A, Aarsland D, Nordhus IH. The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. Int Psychogeriatr/IPA. 2012;24(11):1771-8.
15. Tiraboschi P, Hansen LA, Alford M, Merdes A, Masliah E, Thal LJ, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry. 2002;59(10):946-51.
16. Perry EK, Kerwin J, Perry RH, Blessed G, Fairbairn AF. Visual hallucinations and the cholinergic system in dementia. J Neurol Neurosurg Psychiatry. 1990;53(1):88.
17. Ballard C, Piggott M, Johnson M, Cairns N, Perry R, McKeith I, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol. 2000;48(6):868-76.
18. Shiozaki K, Iseki E, Uchiyama H, Watanabe Y, Haga T, Kameyama K, et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1999;67(2):209-13.
19. Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. Nicotinic receptor abnormalities in Alzheimer's disease. Biol Psychiatry. 2001;49(3):175-84.
20. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord Off J Mov Disord Soc. 2007;22(Suppl 17):S351-7.
21. Ballard C, Johnson M, Piggott M, Perry R, O'Brien J, Rowan E, et al. A positive association between 5HT re-uptake binding sites and depression in dementia with Lewy bodies. J Affect Disord. 2002;69(1-3):219-23.
22. Chen CP, Alder JT, Bowen DM, Esiri MM, McDonald B, Hope T, et al. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem. 1996;66(4):1592-8.
23. Ballard CG, Gauthier S, Cummings JL, Brodaty H, Grossberg GT, Robert P, et al. Management of agitation and aggression associated with Alzheimer disease. Nature Rev Neurol. 2009;5(5):245-55.
24. Dombrovski AY, Mulsant BH, Ferrell RE, Lotrich FE, Rosen JI, Wallace M, et al. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol. 2010;25(1):37-45.
25. Creese B, Ballard C, Jones E. Cognitive impairment in studies of 5HTTLPR and psychosis in Alzheimer's disease: a systematic review. Dementia Geriatr Cognit Disord. 2013;35(3-4):155-64.
26. Sharp SI, Ballard CG, Ziabreva I, Piggott MA, Perry RH, Perry EK, et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dementia Geriatr Cognit Disord. 2008;26(4):330-8.
27. Vallortigara J, Hortobágyi T, Attems J, Aarsland D, Ballard CG, O'Brien J, Francis PT. Correlations between synaptic proteins expression and clinico-pathological features in dementia with Lewy bodies and Parkinson's disease dementia. Society for Neuroscience. 2012; Program No. 621.02 (2012 Neuroscience Meeting Planner. New Orleans, LA).
28. Schulze KL, Littleton JT, Salzberg A, Halachmi N, Stern M, Lev Z, et al. rop, a Drosophila homolog of yeast Sec1 and vertebrate n-Sec1/Munc-18 proteins, is a negative regulator of neurotransmitter release in vivo. Neuron. 1994;13(5):1099-108.
29. Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F, et al. Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010;16(8):522-6.
30. Molloy S, Minett T, O'Brien JT, McKeith IG, Burn DJ. Levodopa use and sleep in patients with dementia with Lewy bodies. Mov Disord Off J Mov Disord Soc. 2009;24(4):609-12.
31. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord Off J Mov Disord Soc. 2008;23(15):2248-50.
32. Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease. Drugs Aging. 2010;27(4):295-310.
33. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2006;14(3):191-210.
34. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nature Rev Neurosci. 2006;7(6):492-500.
35. Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-7.
36. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ. 1992;305(6855):673-8.
37. Sadek J, Rockwood K. Coma with accidental single dose of an atypical neuroleptic in a patient with Lewy body dementia. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2003;11(1):112-3.
38. Aarsland D, Perry R, Larsen JP, McKeith IG, O'Brien JT, Perry EK, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry. 2005;66(5):633-7.
39. Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998;351(9108):1032- 3.
40. Piggott MA, Perry EK, Marshall EF, McKeith IG, Johnson M, Melrose HL, et al. Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biol Psychiatry. 1998;44(8):765-74.
41. Friedman JH. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010;16(9):553-60.
42. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002;63(6):513-5.
43. Onor ML, Saina M, Aguglia E. Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia. Am J Alzheimer's Dis Other Dementias. 2006;21(6):448-53.
44. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shimizu T. Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Progress Neuro-Psychopharmacol Biol Psychiatry. 2003;27(3):549-53.
45. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dementia Geriatr Cognit Disord. 2002;13(2):67-73.
46. McKeith IG, O'Brien JT, Ballard C. Diagnosing dementia with Lewy bodies. Lancet. 1999;354(9186):1227-8.
47. Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356-63.
48. Culo S, Mulsant BH, Rosen J, Mazumdar S, Blakesley RE, Houck PR, et al. Treating neuropsychiatric Symptoms in dementia with Lewy bodies: a randomized controlled-trial. Alzheimer Dis Assoc Disord. 2010 (Epub 2010/07/14).
49. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet. 1999;353(9169):2041-2.
50. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999;340(10):757-63.
51. Hutchinson M, Fazzini E. Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996;61(3):324-5.
52. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17(3):164-71.
53. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;3:CD006504.
54. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004;351(24):2509-18.
55. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031-6.
56. Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord Off J Mov Disord Soc. 2012;27(10):1230-8.
57. Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41-52.
58. Dalfo E, Albasanz JL, Martin M, Ferrer I. Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions. Brain Pathol. 2004;14(4):388-98.
59. Aarsland D, Ballard C, Rongve A, Broadstock M, Svenningsson P. Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia. Curr Neurol Neurosci Rep. 2012;12(5):492-501.
60. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969-77.
61. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-8.
62. Larsson V, Aarsland D, Ballard C, Minthon L, Londos E. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int J Geriatr Psychiatry. 2010;25(10):1030-8.
63. Levin OS, Batukaeva LA, Smolentseva IG, Amosova NA. Efficacy and safety of memantine in Lewy body dementia. Neurosci Behav Physiol. 2009;39(6):597-604.
64. Takahashi S, Mizukami K, Yasuno F, Asada T. Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatr Off J Jpn Psychogeriatr Soc. 2009;9(2):56-61.
65. Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA J Am Med Assoc. 2003;290(15):2015-22.
66. Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591-6.
67. Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2010;6(1):85-95.
68. Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2012;27(4):559-61.
69. Sasai T, Inoue Y, Matsuura M. Effectiveness of pramipexole, a dopamine agonist, on rapid eye movement sleep behavior disorder. Tohoku J Exp Med. 2012;226(3):177-81.
70. Howell MJ, Arneson PA, Schenck CH. A novel therapy for REM sleep behavior disorder (RBD). J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. 2011;7(6):639-44A.
71. Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2010;18(4):371-4.
72. Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry Off J Am Assoc Geriatr Psychiatry. 2009;17(9):744-51.